4 results
10-Q
2024 Q1
IMCR
Immunocore Holdings plc
8 May 24
Quarterly report
7:00am
(Unaudited, in thousands, except share and per share data)
Three Months Ended March 31, | ||||||||
2024 | 2023 | |||||||
Revenue: | ||||||||
Product revenue, net | $ | 70,342 | $ | 51,581 | ||||
Collaboration revenue | 160 | 3,078 | ||||||
Total revenue | 70,502 | 54,659 | ||||||
Cost and operating expenses: | ||||||||
Cost of product revenue | (246) | (216) | ||||||
Research and development expense | (57,459) | (36,572) | ||||||
Selling, general and administrative expense | (39,287) | (32,567) | ||||||
Loss from operations | (26,490) | (14,696) | ||||||
Other income (expense): | ||||||||
Interest income | 8,246 | 3,128 | ||||||
Interest expense | (3,239) | (1,250) | ||||||
Foreign currency loss | (2,406) | (6,013) | ||||||
Other expense, net | (190) | (325) | ||||||
Net loss before income taxes | (24,079) | (19,156) | ||||||
Income tax expense | (357) | (293) | ||||||
Net loss | $ | (24,436) | $ | (19,449) | ||||
Other comprehensive income: | ||||||||
Exchange differences on translation of foreign operations | 897 | 7,434 | ||||||
Total comprehensive loss | (23,539) | (12,015) | ||||||
Basic and diluted net loss per share | $ | (0.49) | $ | (0.40) | ||||
Basic and diluted weighted-average number of shares outstanding | 49,877,218 | 48,183,771 |
10-Q
2024 Q1
IMCR
Immunocore Holdings plc
8 May 24
Quarterly report
7:00am
The following table shows the total share-based compensation expense recorded in the Condensed Consolidated Statements of Operations and Comprehensive Loss (in thousands):
Three Months Ended March 31, | ||||||||
2024 | 2023 | |||||||
Research and development | $ | 1,980 | $ | 1,696 | ||||
Selling, general and administrative | $ | 6,984 | $ | 6,562 |
DEF 14A
IMCR
Immunocore Holdings plc
12 Apr 24
Definitive proxy
4:20pm
The table below illustrates the Company’s expenditure on pay, in comparison to Group’s expenditure on research and development costs. Research and Development is the company’s principal activity and, as such, is the most appropriate metric against which to measure employee expenditure. 2021 was the first year that the Company has prepared a Remuneration Report and as the Company was incorporated on 7 January 2021, and we do not have any historical remuneration to disclose for periods prior to 2021.
| | 2023 ($000)(2) | | | 2022 ($000)(2) | | | 2021 ($000)(2) | |
Group research and development costs | | | 160,971 | | | 107,691 | | | 98,855 |
Total employee pay expenditure(1) | | | 101,877 | | | 83,105 | | | 89,717 |
10-K
2023 FY
IMCR
Immunocore Holdings plc
28 Feb 24
Annual report
7:33am
Year Ended December 31, | ||||||||||||
2023 | 2022 | 2021 | ||||||||||
Revenue: | ||||||||||||
Product revenue, net | $ | 238,735 | $ | 130,013 | $ | — | ||||||
Pre-product revenue, net | — | 10,674 | 4,078 | |||||||||
Total revenue from sale of therapies | 238,735 | 140,687 | 4,078 | |||||||||
Collaboration revenue | 10,693 | 33,674 | 32,406 | |||||||||
Total revenue | 249,428 | 174,361 | 36,484 | |||||||||
Cost and operating expenses: | ||||||||||||
Cost of product revenue | (1,037) | (1,089) | — | |||||||||
Research and development expense | (163,545) | (101,921) | (100,248) | |||||||||
Selling, general and administrative expense | (144,495) | (123,059) | (110,823) | |||||||||
Loss from operations | (59,649) | (51,708) | (174,587) | |||||||||
Other (expense) income: | ||||||||||||
Interest income | 17,986 | 3,756 | 65 | |||||||||
Interest expense | (5,154) | (5,409) | (5,573) | |||||||||
Foreign currency (loss) gain | (13,176) | 14,157 | 289 | |||||||||
Other expense, net | (897) | (1,679) | (73) | |||||||||
Net loss before income taxes | (60,890) | (40,883) | (179,879) | |||||||||
Income tax credit (expense) | 5,603 | (11,660) | (150) | |||||||||
Net loss | $ | (55,287) | $ | (52,543) | $ | (180,029) | ||||||
Other comprehensive income (loss): | ||||||||||||
Exchange differences on translation of foreign operations | 18,412 | (24,358) | (254) | |||||||||
Total comprehensive loss | (36,875) | (76,901) | (180,283) | |||||||||
Basic and diluted net loss per share | $ | (1.13) | $ | (1.15) | $ | (4.24) | ||||||
Basic and diluted weighted-average number of shares outstanding | 48,888,975 | 45,714,923 | 42,488,579 |
- Prev
- 1
- Next